Growth of Value-Based Purchasing and Contracting for Cell & Gene Therapies Part 1
The Self-Insurer • Fri Mar 14 2025
As a political power shift unfolds throughout the halls of Congress, the explosion of cell and gene therapies (CGTs) may be forcing employers to re-think coverage options and get more inventive in their approach to stop-loss coverage, policy limits and exclusions, and payment models. Innovative coverage options are emerging as employee demand accelerates for these costly but potentially lifesaving treatments.
As a political power shift unfolds throughout the halls of Congress, the explosion of cell and gene therapies (CGTs) may be forcing employers to re-think coverage options and get more inventive in their approach to stop-loss coverage, policy limits and exclusions, and payment models. Innovative coverage options are emerging as employee demand accelerates for these costly but potentially lifesaving treatments.
Read the full article on page 8 here: March 2025 The Self-Insurer by The Self-Insurer Magazine
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.